title: ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
abstract: Pancreatic cancer is one of the most aggressive malignant diseases. We recently reported that N-cadherin plays a key role in tumor progression and metastasis in pancreatic cancer. For this study, we sought to determine if an N-cadherin-blocking peptide (ADH-1) could prevent N-cadherin-mediated tumor progression in a mouse model for pancreatic cancer. The effect of ADH-1 on N-cadherin-mediated cell scattering and migration on collagen I was examined using pancreatic cancer cells. We also examined the influence of ADH-1 on cell apoptosis. Furthermore, in vivo animal studies were performed using orthotopic injection of N-cadherin overexpressing BxPC-3 cells with or without ADH-1 treatment. BxPC-3 and Capan-1 cells exhibited increased expression of N-cadherin in response to collagen I. This increase in N-cadherin promoted cell scattering and migration in response to collagen I. ADH-1 prevented these changes, but did not inhibit upregulation of N-cadherin. TUNEL assays and immunoblots for caspase-3 showed that ADH-1 induced apoptosis in a concentration dependent and N-cadherin dependent manner in pancreatic cancer cells. ADH-1 treatment resulted in significant reductions in tumor growth and lung metastasis in a mouse model for pancreatic cancer. The N-cadherin antagonist, ADH-1 has significant antitumor activity against N-cadherin-expressing cells using in vitro assays and in an orthotopic mouse model for pancreatic cancer, raising the possibility that N-cadherin antagonists have therapeutic potential for the treatment of pancreatic cancer in humans.
authors.affiliation: Department of Oral Biology, University of Nebraska Medical Center, Omaha, NE 68198-7696, USA.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Shintani
authors.forename: Yuri
authors.initials: Y
authors.lastname: Fukumoto
authors.forename: Nina
authors.initials: N
authors.lastname: Chaika
authors.forename: Paul M
authors.initials: PM
authors.lastname: Grandgenett
authors.forename: Michael A
authors.initials: MA
authors.lastname: Hollingsworth
authors.forename: Margaret J
authors.initials: MJ
authors.lastname: Wheelock
authors.forename: Keith R
authors.initials: KR
authors.lastname: Johnson
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism*; D017209:Apoptosis; D015820:Cadherins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D002448:Cell Adhesion; D002465:Cell Movement; D003094:Collagen / Q000378:metabolism; D018450:Disease Progression; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D006801:Humans; D015151:Immunoblotting; D020287:In Situ Nick-End Labeling; D051379:Mice; D008819:Mice, Nude; D009842:Oligopeptides / Q000494:pharmacology*; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000517:prevention & control*; D010456:Peptides, Cyclic / Q000494:pharmacology*; D034741:RNA, Small Interfering / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: C518575:ADH-1 pepide; D015703:Antigens, CD; C050361:CDH2 protein, human; D015820:Cadherins; D009842:Oligopeptides; D010456:Peptides, Cyclic; D034741:RNA, Small Interfering; D003094:Collagen